Autosomal Recessive Limb-Girdle Muscular Dystrophy Caused by TCAP (Telethonin) Mutations

Other names
Types
Causes
Common symptoms
Diagnostic tests
Non-pharmacological treatments (therapies & other supports)
Drug treatments
Dietary molecular supplements
Immunity-booster / regenerative / stem-cell drugs
Surgeries / procedures
Prevention & safety tips
When to see a doctor (or go urgently)
What to eat — and what to avoid
Frequently asked questions
Non-pharmacological treatments (therapies & other supports)
Drug treatments
Dietary molecular supplements
Immunity-booster / regenerative / stem-cell drugs
Surgeries / procedures
Prevention & safety tips
When to see a doctor (or go urgently)
What to eat — and what to avoid
Frequently asked questions
You Might Also Like This :

Telethonin-related limb-girdle muscular dystrophy is a rare, inherited muscle disease. It weakens the muscles around the hips and shoulders (the “limb girdles”). People usually notice trouble climbing stairs, rising from a chair, running, or lifting arms above the head. The weakness can also reach some lower-leg muscles and cause foot drop. The condition is autosomal recessive. That means a person gets a faulty copy of the same gene from each parent. The gene is called TCAP, and it makes a small muscle protein named telethonin. Telethonin sits at the Z-disc of the muscle fiber and helps anchor the giant protein titin so the muscle can handle stretch and force. When telethonin is missing or not working, the muscle fiber structure becomes fragile, fibers break down over time, and weakness slowly increases. Creatine kinase (CK) in the blood is often high because damaged fibers leak CK. There is no cure yet, but diagnosis is possible with genetic testing, and supportive care can help with strength, safety, and quality of life. Nature+2PLOS+2

LGMDR7 is a rare, inherited muscle disease in which both copies of the TCAP gene are altered. TCAP encodes telethonin, a small protein that helps anchor titin at the Z-disc inside muscle fibers. When telethonin is missing or faulty, muscle fibers become fragile and gradually weaken, especially around the hips and shoulders (the “limb-girdle” region). Symptoms often begin in the first or second decade of life with difficulty running, climbing stairs, or rising from the floor; some people also show calf enlargement and later need walking support. Progression varies, and some cohorts report little or no heart/respiratory involvement, while others describe cardiomyopathy—so regular heart and lung checks are important. There is no approved disease-modifying drug yet; care focuses on rehabilitation, heart-failure risk management, breathing support, and fall/contracture prevention. PubMed+4Nature+4PMC+4

Modern naming uses LGMDR7 (the “R” means recessive) instead of the older label LGMD2G. This change came from an international consensus to make LGMD names clearer across genes and inheritance patterns. nmd-journal.com+1

Other names

LGMD2G (older name)
LGMDR7, telethonin-related (current naming in many papers)
Telethoninopathy
TCAP-related limb-girdle muscular dystrophy
Limb-girdle muscular dystrophy due to telethonin deficiency PubMed+1

Types

Doctors do not split this disease into formal “types” the way they do for some other conditions. But you will see two useful ways to think about variation:

By age and pattern of weakness

Classic limb-girdle pattern with hip and shoulder weakness that often starts in late childhood or the teen years. Calf muscles may look big (true hypertrophy or fatty change). Some people lose the ability to walk in adulthood; others keep walking much longer. Heart and breathing muscles are usually okay, but mild heart issues have been reported. PLOS+1
Disto-proximal or later-onset patterns have been described, including cases with more obvious lower-leg weakness or later adult onset. These are less common. PubMed+1

By the mutation’s effect on the protein

Loss-of-function (nonsense, frameshift, splice) leading to very low or no telethonin.
Missense changes that produce a misfolded or unstable telethonin that cannot bind titin well.
Larger deletions/complex variants that remove key parts of TCAP.
These categories help explain severity but do not perfectly predict it. Different families with the same change can have different courses. Nature+1

Causes

The main cause is the same in every person with this diagnosis: two disease-causing variants (mutations) in the TCAP gene. Below are 20 causes and contributors, grouped for clarity.

A. Genetic and molecular causes (core disease drivers)

Biallelic TCAP mutations (autosomal recessive inheritance). This is the fundamental cause. Nature
Nonsense mutations that introduce a stop signal and truncate telethonin.
Frameshift mutations that disrupt the protein code and destroy function.
Splice-site mutations that make the cell cut and paste the gene message incorrectly.
Missense mutations that swap one amino acid for another and weaken telethonin’s binding to titin.
Large deletions or complex rearrangements that remove critical gene segments.
Nonsense-mediated decay of the faulty messenger RNA, leaving the cell with too little telethonin.
Telethonin–titin binding failure at the Z-disc, destabilizing the sarcomere under mechanical stress. Nature+1

B. Genetic background and population factors

Founder variants in specific regions (for example, early series from Brazil), increasing local risk. Nature+1
Consanguinity (parents related by blood) increases the chance that the same rare variant is inherited from both sides.
Modifier genes in other muscle proteins (for example, titin or proteolytic pathways) may shape severity, though data are limited. MDPI

C. Cellular stressors that worsen muscle injury (do not “cause” the gene defect, but can speed damage)

Repeated eccentric/mechanical strain of weak muscle (heavy downhill walking, sudden unaccustomed loads).
Oxidative stress and inflammation after fiber damage.
Poor recovery after minor injuries because the structural scaffold is fragile without normal telethonin.
Nutritional depletion or severe weight loss, which reduces muscle repair capacity.
Serious infections or fevers, which can temporarily worsen weakness and increase CK.
Myotoxic drugs (very rare) may aggravate muscle pain and CK; always discuss statins, certain antivirals, or alcohol excess with your clinician.
Immobilization and inactivity, which drive deconditioning and faster loss of function.
Obesity, which increases mechanical load and fatigue.
Vitamin D deficiency and untreated sleep apnea, which worsen fatigue and functional reserve; correcting them won’t cure the disease but can help overall function.

Common symptoms

Trouble climbing stairs—thigh and hip muscles are weak, so each step feels heavy.
Difficulty rising from a chair or the floor—you may push on thighs or use “Gowers’ maneuver” to stand.
Waddling or Trendelenburg gait—pelvic muscles cannot hold the hips level while walking.
Frequent tripping or foot drop—front shin muscles can weaken, so toes catch the ground. PubMed+1
Trouble lifting arms overhead—weak shoulder girdle muscles make overhead tasks tiring.
Calf enlargement—calf muscles may look big from true enlargement or fatty change; they can still be weak. PLOS
Muscle cramps or aching—especially after activity or at night.
Fatigue—extra effort is needed for routine tasks, so you tire faster.
Falls—weak hip and ankle control make balance harder.
Slow running speed—sports become challenging early on.
Difficulty carrying heavy objects—shoulder and arm girdle strength is reduced.
Stiffness or tight tendons—calf and hamstring tightness may develop over time (contractures).
Back discomfort—weak trunk support changes posture and loads the spine.
Occasional palpitations or breathlessness—heart involvement is uncommon but reported in some families; always mention new heart or breathing symptoms to your clinician. malacards.org
Emotional stress—living with a progressive condition can cause worry or low mood; support matters.

Diagnostic tests

A) Physical examination

Gait observation
Your clinician watches you walk. A side-to-side hip drop (Trendelenburg sign) or a “waddle” points to hip abductor weakness typical of limb-girdle patterns.
Gowers’ maneuver
From the floor, you may push on your thighs to stand up. This classic sign reflects proximal weakness of hip and thigh muscles.
Timed functional tests
Simple tasks—time to stand from a chair, time to climb four stairs, 10-meter walk—give an objective track of change over months.
Posture and spine check
They look for lordosis (swayback) or scapular winging, which can happen when shoulder girdle muscles are weak.
Contracture assessment
Ankles, knees, and hips are checked for tightness. Gentle stretching plans come from these measurements.

B) Manual muscle and functional strength tests

Manual Muscle Testing (MMT)
The examiner grades strength from 0 (no movement) to 5 (normal) in key muscles: hip flexors/extensors, abductors/adductors, knee extensors/flexors, shoulder abductors, and ankle dorsiflexors. It maps where weakness is greatest (usually hips/shoulders first).
Hand-held dynamometry
A small device measures force in kilograms or newtons. It is more sensitive than MMT for detecting small changes.
Six-Minute Walk Test (6MWT)
You walk back and forth for six minutes. Distance covered reflects endurance and safety. It helps track treatment response or disease pace.
Timed Up and Go (TUG)
Stand up, walk three meters, turn, return, and sit. It screens for fall risk and need for aids.
Stair-climb power test
Climbing a set number of steps as fast as safely possible shows hip and thigh power—often a main problem in limb-girdle dystrophies.

C) Laboratory and pathological tests

Serum creatine kinase (CK)
CK is usually elevated, sometimes many times the upper limit, because damaged muscle leaks CK. CK can fluctuate (for example after exercise). malacards.org
Aldolase, AST/ALT, LDH
These can also be high from muscle, not just liver. Doctors interpret them alongside CK and your story.
Genetic testing—targeted panel including TCAP
Modern labs use next-generation sequencing (NGS) panels for muscle diseases. This is the key test: it can find two disease-causing TCAP variants, confirming the diagnosis. Some labs also add copy-number methods (e.g., MLPA or NGS-CNV) to catch larger deletions. NCBI
Sanger confirmation and family testing
Once a variant is found, Sanger sequencing confirms it. Parents and siblings may be tested to understand inheritance and risks.
Muscle biopsy with immunohistochemistry
If genetics are unclear, a biopsy can show dystrophic changes and loss or reduction of telethonin staining. Western blot may also show low telethonin. Electron microscopy can reveal Z-disc disruption. These findings support TCAP involvement when genetics is uncertain. PubMed+1
Cardiac blood tests (as needed)
If there are heart symptoms, BNP or troponin may be checked; most telethonin-LGMD patients do not have major cardiomyopathy, but exceptions exist, so clinicians stay alert. PubMed+1

D) Electrodiagnostic tests

Electromyography (EMG)
EMG typically shows a myopathic pattern: short-duration, small-amplitude motor unit potentials with early recruitment. This points to muscle fiber disease rather than nerve disease. PubMed
Nerve conduction studies (NCS)
NCS are usually normal, which helps separate this condition from peripheral neuropathies that slow nerve signals. EMG and NCS together build confidence that the problem is muscle-based. PubMed

E) Imaging tests

Muscle MRI (thighs, pelvis, calves)
MRI shows which muscles are most affected and how much fat has replaced muscle. In telethonin-related LGMD, radiologists may see selective patterns in thigh and calf muscles that support the diagnosis and help rule out other LGMD subtypes. MRI also tracks progression without repeated biopsies. PubMed
Cardiac evaluation if symptoms or family history
This can include ECG and echocardiogram. Many case series report no cardiomyopathy, but some reports note heart involvement; clinicians use symptoms to guide how often to check. PubMed+1

Non-pharmacological treatments (therapies & other supports)

For each item: description (~150 words), purpose, mechanism.

Individualized, sub-maximal exercise program (PT-guided)
Description. Supervised, moderate-intensity aerobic + gentle resistance exercise helps people maintain cardiovascular fitness, functional mobility, and mood without over-straining fragile muscle fibers. Plans usually include short bouts, adequate rest, and avoidance of “exercise to exhaustion.” Overly intense or eccentric-heavy regimens can worsen soreness and fatigue. Programs are adjusted as weakness progresses.
Purpose. Maintain endurance, slow deconditioning, preserve independence, and reduce cardiometabolic risk.
Mechanism. Aerobic training improves mitochondrial efficiency and oxygen delivery; light resistance preserves motor-unit recruitment and neuromuscular coordination without causing high mechanical stress. Evidence across muscular dystrophies suggests supervised training is generally safe and can modestly improve function. Muscular Dystrophy Association+3Cochrane+3PMC+3
Physical therapy for flexibility & contracture prevention
Description. Daily range-of-motion work, gentle stretching, and night splints help keep joints supple (hips, knees, ankles, shoulders). Therapists teach safe transfer techniques and pacing.
Purpose. Prevent contractures, reduce falls, and ease caregiving.
Mechanism. Regular low-load stretching maintains tendon and muscle length and reduces connective-tissue stiffening that follows chronic weakness and immobility. Muscular Dystrophy Association
Occupational therapy (OT) & energy conservation
Description. OT addresses dressing, bathing, kitchen work, and school/office ergonomics; it introduces adaptive tools, safe transfer methods, and task sequencing to reduce fatigue.
Purpose. Maintain activities of daily living (ADLs) and independence.
Mechanism. Task simplification and leverage devices reduce the mechanical load on weakened proximal muscles. Muscular Dystrophy Association
Assistive mobility devices (canes, forearm crutches, rollators, wheelchairs)
Description. Timely device use prevents unsafe compensatory gait, reduces falls, and extends community mobility. Choice evolves with disease stage.
Purpose. Safety, participation, and joint protection.
Mechanism. Offloading reduces torque on hip abductors and knee extensors; wheels convert endurance-limited walking into sustainable mobility. LGMD Awareness Foundation
Orthoses (AFOs, KAFOs) & ankle stabilization
Description. Braces prevent foot drop, stabilize ankles, and may improve push-off.
Purpose. Improve gait efficiency and reduce trips/falls.
Mechanism. External support substitutes for weak dorsiflexors/plantarflexors, lowering energy cost of walking. LGMD Awareness Foundation
Fall-prevention home modifications
Description. Remove tripping hazards, install grab bars/railings, improve lighting, and use non-slip footwear.
Purpose. Minimize fracture risk and hospitalization.
Mechanism. Environmental risk reduction compensates for proximal weakness and impaired balance. LGMD Awareness Foundation
Bone health program (nutrition, screening, fracture prevention)
Description. Ensure adequate calcium & vitamin D intake, screen for low bone density if mobility declines, and address fall risks.
Purpose. Prevent osteopenia/osteoporosis and fractures in reduced-mobility states.
Mechanism. Vitamin D optimizes calcium absorption; weight-bearing (as tolerated) and balance work stimulate bone remodeling. (Note: population-wide fracture prevention from supplements alone is mixed; personalize to labs and risk.) Frontiers+2PMC+2
Respiratory surveillance & non-invasive ventilation (NIV) when indicated
Description. Regular pulmonary function tests; if nocturnal hypoventilation or weak cough emerges, introduce NIV (e.g., BiPAP) and mechanical cough assist. Vaccinations (influenza, pneumococcal) are encouraged.
Purpose. Prevent respiratory failure, infections, and hospitalizations.
Mechanism. NIV supports alveolar ventilation during sleep; cough-assist increases expiratory flow to clear secretions when expiratory muscles weaken. Chest Journal+2PMC+2
Cardiac surveillance & early heart-failure care
Description. Baseline and periodic ECG/echo ± Holter depending on phenotype; early referral for cardiology if systolic dysfunction or arrhythmias appear.
Purpose. Detect treatable cardiomyopathy/arrhythmia early.
Mechanism. Standard HF tools (ACEi/ARB/ARNi, beta-blockers, MRAs, SGLT2 inhibitors) follow evidence in non-LGMD cardiomyopathies and apply when LV dysfunction occurs. AHA Journals+1
Speech/swallow therapy if bulbar symptoms
Description. Evaluation for dysphagia, diet texture modification, and safe-swallow strategies.
Purpose. Reduce aspiration risk and maintain nutrition/hydration.
Mechanism. Compensatory techniques and targeted exercises optimize remaining motor control. LGMD Awareness Foundation
Nutrition counseling (protein adequacy, weight management, HF-aware sodium limits)
Description. Tailor calories to activity; emphasize lean protein, fiber, and salt restriction if heart failure is present; ensure hydration.
Purpose. Preserve muscle mass, avoid sarcopenic obesity, and reduce edema.
Mechanism. Adequate protein supports muscle protein turnover; lower sodium can reduce fluid retention in HF. Muscular Dystrophy Association
Pacing & fatigue management (activity diaries, rest blocks)
Description. Break tasks into chunks, alternate exertion with rest, and schedule demanding activities earlier in the day.
Purpose. Prevent overuse and “crash” cycles.
Mechanism. Energy budgeting matches reduced oxidative capacity and muscle endurance. Muscular Dystrophy Association
Psychological support & peer groups
Description. Counseling and condition-specific communities help with adjustment, motivation for rehab, and caregiver strain.
Purpose. Improve QoL and adherence to long-term care.
Mechanism. Social support and CBT strategies mitigate anxiety/depression linked to progressive conditions. Muscular Dystrophy Association
School/workplace accommodations
Description. Seating/desk ergonomics, lift access, flexible schedules, remote work options.
Purpose. Maintain education and employment.
Mechanism. Reduces participation barriers from proximal weakness/fatigue. LGMD Awareness Foundation
Anesthesia & peri-operative precautions
Description. Share a muscular dystrophy anesthesia alert with surgical teams; avoid prolonged immobilization; plan post-op respiratory support and early rehab.
Purpose. Reduce anesthesia complications and deconditioning.
Mechanism. Anticipatory planning addresses risks of respiratory weakness and rhabdomyolysis triggers. LGMD Awareness Foundation
Electrical stimulation (select cases, supervised)
Description. Low-intensity neuromuscular electrical stimulation has been studied in LGMD with mixed findings; if used, it should be carefully dosed and monitored.
Purpose. Attempt to preserve muscle bulk and function.
Mechanism. External pulses recruit motor units, but overuse could exacerbate damage—hence specialist oversight. jnnp.bmj.com+1
Cough-augmentation & airway clearance techniques
Description. Manual assisted cough, breath-stacking, and mechanical insufflation-exsufflation during infections.
Purpose. Reduce pneumonia risk and hospital stays.
Mechanism. Increases peak cough flow to clear secretions when expiratory muscles are weak. Chest Journal+1
Vaccination (influenza, COVID-19, pneumococcal as locally advised)
Description. Keep immunizations current; respiratory infections can be harder to clear in neuromuscular disease.
Purpose. Prevent severe infections and exacerbations.
Mechanism. Induced immunity lowers infection risk and complications. Chest Journal
Genetic counseling (family planning, carrier testing)
Description. Discuss inheritance (autosomal recessive), options for carrier testing of relatives, and prenatal/preimplantation genetic testing if desired.
Purpose. Informed decisions and early diagnosis.
Mechanism. Identifies carriers and recurrence risk; detects affected embryos/fetuses when families choose testing. NCBI
Clinical-trial engagement & registries
Description. Enroll in LGMD registries and discuss trials (e.g., emerging AAV-TCAP concepts).
Purpose. Access to novel therapies and contribute to research.
Mechanism. Aggregated data accelerates development; trials provide structured monitoring. (Investigational only; no approved TCAP gene therapy yet.) mdaconference.org+1

Drug treatments

LGMDR7 itself has no FDA-approved disease-modifying drug. When patients develop heart failure (HFrEF) or arrhythmias, standard guideline-directed medical therapy (GDMT) applies. Doses below are adult starting/typical targets; individualize with a cardiologist. Labels linked are from accessdata.fda.gov.

Sacubitril/valsartan (ENTRESTO) – ARNi
Class. Angiotensin receptor–neprilysin inhibitor.
Dose/Time. Common start 24/26 mg to 49/51 mg BID, uptitrate as tolerated (after 36-hour ACEi washout).
Purpose. Reduce CV death/HF hospitalization in chronic HF with reduced EF.
Mechanism. Blocks RAAS via ARB (valsartan) + enhances natriuretic peptides (sacubitril).
Key adverse effects. Hypotension, hyperkalemia, renal effects; fetal toxicity boxed warning. FDA Access Data+1
Carvedilol (COREG) – beta-blocker
Class. Nonselective β + α1 blocker.
Dose/Time. Start 3.125 mg BID, uptitrate every 2 weeks to 25–50 mg BID.
Purpose. Lowers mortality and HF hospitalization; benefits across HF.
Mechanism. Reduces sympathetic drive and myocardial oxygen demand; improves remodeling.
Side effects. Bradycardia, hypotension, fatigue; caution in decompensated HF. FDA Access Data+1
Metoprolol succinate (TOPROL-XL) – beta-blocker
Class. β1-selective blocker (extended-release).
Dose/Time. Start 12.5–25 mg daily, titrate to 200 mg daily as tolerated.
Purpose. Reduces composite mortality + hospitalization in HF.
Mechanism. Blunts sympathetic cardiotoxicity and arrhythmia risk.
Side effects. Bradycardia, fatigue. FDA Access Data+1
Lisinopril (ZESTRIL/PRINIVIL) – ACE inhibitor
Class. ACEi.
Dose/Time. Start 2.5–5 mg daily, titrate; avoid with ARNi/ARB duplicate.
Purpose. Foundational HF therapy when ARNi not used/tolerated.
Mechanism. RAAS blockade reduces afterload, remodeling.
Side effects. Cough, hyperkalemia, renal effects; fetal toxicity boxed warning. FDA Access Data+1
Valsartan/Losartan – ARBs (alternative to ACEi if cough/angioedema history)
Class. ARB.
Dose/Time. Valsartan often 40–80 mg BID then up; Losartan 25–50 mg daily then up.
Purpose/Mechanism/SE. RAAS blockade like ACEi (without cough), similar monitoring. (Use ARB labeling where applicable.) FDA Access Data
Spironolactone (ALDACTONE/CAROSPIR) – MRA
Class. Mineralocorticoid receptor antagonist.
Dose/Time. 12.5–25 mg daily; adjust for K⁺/renal function.
Purpose. Improves survival and reduces HF hospitalization in symptomatic HFrEF.
Mechanism. Blocks aldosterone’s pro-fibrotic, sodium-retentive actions.
Side effects. Hyperkalemia, gynecomastia (less with eplerenone). FDA Access Data+1
Eplerenone (INSPRA) – MRA
Class. Selective mineralocorticoid receptor antagonist.
Dose/Time. Often 25 mg daily, then 50 mg daily.
Purpose. Alternative to spironolactone, with fewer endocrine adverse effects.
Mechanism/SE. As above; monitor K⁺/renal. FDA Access Data+1
Dapagliflozin (FARXIGA) – SGLT2 inhibitor
Class. SGLT2i.
Dose/Time. 10 mg once daily (indicated in HF regardless of diabetes).
Purpose. Reduces CV death/HF hospitalizations in HFrEF/HFpEF.
Mechanism. Natriuresis, improved energetics, kidney-cardio protection.
Side effects. Genital mycotic infections, volume depletion; educate on sick-day rules. FDA Access Data+2FDA Access Data+2
Empagliflozin (JARDIANCE) – SGLT2 inhibitor
Class. SGLT2i.
Dose/Time. 10 mg once daily for HF indication.
Purpose/Mechanism/SE. Similar to dapagliflozin; HF benefit across EF spectrum. FDA Access Data+1
Furosemide (LASIX) – loop diuretic
Class. Loop diuretic.
Dose/Time. Typical start 20–40 mg once/twice daily, titrate to euvolemia.
Purpose. Relieve edema/congestion (symptom control).
Mechanism. Inhibits NKCC2 in loop of Henle → natriuresis/diuresis.
Side effects. Electrolyte loss, dehydration, hypotension. FDA Access Data+1
Torsemide (DEMADEX) – loop diuretic
Class. Loop diuretic (better oral bioavailability).
Dose/Time. Often 10–20 mg daily, adjust to response.
Purpose/Mechanism/SE. As with furosemide; may be preferred in diuretic resistance. FDA Access Data+1
Metolazone – thiazide-like diuretic (add-on)
Class. Distal tubule diuretic.
Dose/Time. 2.5–5 mg intermittently with loops in refractory edema (clinician-directed).
Purpose. Overcome diuretic resistance.
Mechanism. Sequential nephron blockade enhances natriuresis. (Use label appropriate to brand/generic in your locale.) FDA Access Data
Ivabradine (CORLANOR)
Class. If-current inhibitor (sinus node).
Dose/Time. Start 5 mg BID (or 2.5 mg if brady-prone), adjust to HR 50–60 bpm; only if sinus rhythm, HR ≥70 on max β-blocker.
Purpose. Lowers HF hospitalization in select HFrEF.
Mechanism. Slows heart rate without reducing contractility.
Side effects. Luminous phenomena, bradycardia, AF risk. FDA Access Data
Amiodarone (PACERONE/CORDARONE)
Class. Class III antiarrhythmic.
Dose/Time. Load 800–1600 mg/day, taper to 200–400 mg/day maintenance under specialist care.
Purpose. Treat life-threatening ventricular arrhythmias or refractory AF where needed.
Mechanism. Prolongs action potential; multi-channel effects.
Side effects. Thyroid, pulmonary, hepatic toxicity—requires monitoring. FDA Access Data+1
Apixaban (ELIQUIS) (if atrial fibrillation occurs)
Class. Direct oral anticoagulant (Factor Xa inhibitor).
Dose/Time. 5 mg BID (or 2.5 mg BID if ≥2 dose-reduction criteria).
Purpose. Stroke prevention in non-valvular AF.
Mechanism. Inhibits Xa → reduces thrombin generation.
Side effects. Bleeding risk; renal/hepatic considerations. FDA Access Data+1
ACEi alternatives (enalapril/ramipril)
Class. ACE inhibitors.
Dose/Time. Enalapril 2.5 mg BID up; Ramipril 1.25–2.5 mg daily up.
Purpose/Mechanism/SE. As with lisinopril; use label dosing and monitor. FDA Access Data
ARB alternative (candesartan/losartan)
Class. ARB.
Dose/Time. Candesartan 4–8 mg daily up; Losartan 25–50 mg daily up.
Purpose. For ACEi-intolerant or when ARNi not suitable.
Mechanism/SE. AT1 blockade, monitor K⁺/creatinine and blood pressure. FDA Access Data
Hydralazine–isosorbide dinitrate (H-ISDN)
Class. Direct vasodilator + nitrate.
Dose/Time. Multiple daily dosing (e.g., 20/37.5 mg TID), per label.
Purpose. Alternative afterload/preload reduction when RAAS blockade isn’t tolerated; added benefit in select populations.
Mechanism. Arteriolar dilation (hydralazine) + venodilation (ISDN). (Use specific US label.) FDA Access Data
Digoxin (selected symptomatic patients with AF or persistent symptoms)
Class. Cardiac glycoside.
Dose/Time. Low dose targeting serum 0.5–0.9 ng/mL.
Purpose. Rate control in AF and symptom relief in HFrEF.
Mechanism. Inhibits Na⁺/K⁺-ATPase → increased inotropy; vagotonic effects. (Use label in your region.) PMC
Loop-plus-thiazide strategy (e.g., torsemide + metolazone) under supervision
Class. Diuretic synergy (not a single drug).
Dose/Time. Intermittent metolazone with loop; careful lab monitoring.
Purpose. Break diuretic resistance and relieve refractory congestion.
Mechanism. Sequential nephron blockade boosts natriuresis. FDA Access Data

Important: These medicines treat heart failure/arrhythmias that can occur in some LGMD subtypes; they do not treat the underlying TCAP mutation. Always tailor to each person’s cardiac status, kidney function, potassium, and blood pressure. AHA Journals

Dietary molecular supplements

Evidence in muscular dystrophies is evolving; supplements do not replace rehab/HF care. Always screen for interactions and watch for placebo effects.

Creatine monohydrate
What it is & dose. A phosphate donor that recharges ATP in muscle; common regimen 3–5 g/day (or 0.1 g/kg/day).
Function/mechanism. In muscular dystrophies, meta-analyses show modest strength gains and improved activities of daily living in some trials, likely via increased phosphocreatine stores and better force output in partially functioning fibers.
Caution. Hydrate well; check kidney function if other risks. PMC+1
Coenzyme Q10 (ubiquinone)
Dose. Often 100–300 mg/day with fat-containing meals; serum-level guided in studies.
Function/mechanism. Electron-transport chain cofactor supporting mitochondrial ATP; small trials (mainly DMD) showed strength improvements when added to steroids; data in LGMD are limited.
Caution. Can lower warfarin effect; discuss with cardiology if anticoagulated. PMC+1
L-carnitine
Dose. 1–2 g/day (tartrate or acetyl-L-carnitine forms).
Function/mechanism. Transports long-chain fatty acids into mitochondria; reviews suggest potential to reduce exercise-induced muscle damage and soreness; clinical data in neuromuscular disease are mixed.
Caution. GI upset possible; interact with certain antibiotics (rare). PMC+2PubMed+2
Vitamin D
Dose. Usually 600–1000 IU/day for adults (individualize to serum 25-OH D).
Function/mechanism. Supports bone health in low-mobility states; necessary to pair with dietary calcium.
Caution. Avoid megadoses without deficiency; personalize—population fracture-prevention benefits are mixed. Frontiers+1
Omega-3 fatty acids (EPA/DHA)
Dose. 1–2 g/day EPA+DHA (combined), food-first via oily fish when possible.
Function/mechanism. Anti-inflammatory effects; evidence shows reduced post-exercise inflammation/soreness in general populations; NMD-specific data are limited/heterogeneous.
Caution. Bleeding risk at high doses with anticoagulants. PMC+2PMC+2
Protein optimization (whey/casein as needed)
Dose. Target ~1.0–1.2 g/kg/day total protein (diet + supplements), adapted to kidney function.
Function/mechanism. Supports muscle protein turnover and recovery alongside PT.
Caution. Excess adds calories; coordinate with dietitian, especially if HF fluid/sodium limits. Muscular Dystrophy Association
Calcium (diet-first; supplement if short)
Dose. Fill the gap to ~1000–1300 mg/day total intake by age.
Function/mechanism. Bone mineralization during reduced weight bearing.
Caution. Avoid excessive supplements; prioritize food sources. Frontiers
Antioxidant-rich foods (berries, greens) ± multivitamin
Dose. Food-first patterns; low-dose multivitamin only if dietary gaps exist.
Function/mechanism. Broad micronutrient sufficiency for neuromuscular health; direct LGMD data limited but general benefits plausible.
Caution. Avoid high-dose single antioxidants without indication. Muscular Dystrophy Association
Magnesium (if documented low or cramps)
Dose. 200–400 mg/day (elemental), titrate to GI tolerance.
Function/mechanism. Neuromuscular excitability stabilization; may help cramps/sleep.
Caution. Diarrhea at high doses; adjust if CKD. Muscular Dystrophy Association
Fiber & omega-3-rich dietary pattern
Dose. Consistent inclusion of legumes, nuts, seeds, vegetables, whole grains, oily fish.
Function/mechanism. Weight, glycemic, and cardiometabolic support relevant to mobility limitations and HF risk.
Caution. Balance with any fluid restrictions in HF. Muscular Dystrophy Association

Immunity-booster / regenerative / stem-cell drugs

There are no FDA-approved “immunity boosters” or stem-cell drugs for LGMDR7. The most scientifically plausible regenerative avenue is gene therapy (AAV-TCAP), but it’s pre-clinical/early-stage and not available as standard care. Below are research directions, explained plainly — not recommendations, no dosing outside trials:

AAV-TCAP gene replacement — Delivers a healthy TCAP gene to muscle to restore telethonin; animal studies show telethonin expression restoration and structural rescue. (Investigational; dosing only in trials.) mdaconference.org+1
Other LGMD gene therapies (platform learnings) — Ongoing AAV work in other LGMDs (e.g., sarcoglycans, calpain-3) informs delivery, dosing, and safety, potentially benefiting future TCAP programs. Muscular Dystrophy Association
Myostatin/activin pathway inhibitors — Aims to increase muscle mass by lifting endogenous growth brakes; mixed results in muscular dystrophies, none approved for LGMD. (Trial-only.) Frontiers
Exon/read-through or RNA approaches — Gene-specific strategies exist for other dystrophies; no approved TCAP-specific RNA therapy yet. (Research concept.) PMC
Cell therapies — Satellite cell or mesoangioblast infusions remain experimental with logistical and immune hurdles; not approved for LGMD. (Trial-only.) Frontiers
Metabolic support co-therapies (e.g., CoQ10) — Adjuncts studied mainly in DMD may help bioenergetics; not disease-modifying in LGMD and not stem-cell drugs. (Supplement category above.) PMC

Surgeries / procedures

Contracture release / tendon lengthening
Why. When ankles or knees develop fixed tightness despite therapy, surgical release can improve position, bracing, and hygiene. LGMD Awareness Foundation
Spinal deformity surgery (if scoliosis severe)
Why. Improve sitting balance, comfort, and skin integrity in advanced weakness; carefully planned with respiratory assessment. LGMD Awareness Foundation
Pacemaker or ICD (device implantation)
Why. If conduction disease or malignant arrhythmias arise, devices reduce risk of syncope or sudden death. heartrhythmjournal.com
Tracheostomy (select advanced respiratory failure)
Why. Long-term ventilatory support when non-invasive strategies fail or are not tolerated. Chest Journal
Feeding tube (PEG) if severe dysphagia/weight loss
Why. Ensure adequate nutrition and aspiration reduction when oral intake is unsafe or insufficient. LGMD Awareness Foundation

Prevention & safety tips

Genetic counseling for family members; understand autosomal recessive risks. NCBI
Regular PT/OT to slow deconditioning and prevent contractures. Muscular Dystrophy Association
Fall-proof the home and use mobility aids early rather than late. LGMD Awareness Foundation
Routine cardiac screening (ECG/echo ± Holter). AHA Journals
Pulmonary check-ups and vaccinations; start NIV/cough-assist when indicated. Chest Journal
Avoid maximal/eccentric overexertion; choose paced, supervised activity. Muscular Dystrophy Association
Bone health: adequate vitamin D/calcium and safe weight-bearing as tolerated. Frontiers
Heart-failure diet cautions (sodium, fluids if prescribed by cardiology). Muscular Dystrophy Association
Anesthesia alert for any surgery; plan post-op respiratory support. LGMD Awareness Foundation
Enroll in registries/trials to access emerging options. Muscular Dystrophy Association

When to see a doctor (or go urgently)

Right away / emergency: new chest pain, fainting, palpitations with dizziness, severe shortness of breath, fever with thick chest secretions not clearing, or a big drop in urine output with swelling. These can indicate arrhythmia, heart failure decompensation, or infection. AHA Journals+1
Soon (days): noticeably worse walking or falls, new swallowing problems, progressive morning headaches or non-refreshing sleep (possible nocturnal hypoventilation). Chest Journal
Routine (weeks): establish care with neuromuscular, cardiology, pulmonary, rehab teams; plan annual or interval assessments per your clinicians. LGMD Awareness Foundation

What to eat — and what to avoid

Eat balanced meals with lean proteins (fish, poultry, legumes) to support muscle maintenance. Avoid ultra-processed, low-protein diets that accelerate muscle loss. Muscular Dystrophy Association
Eat high-fiber foods (vegetables, fruits, whole grains) for gut health and weight control; avoid excessive refined sugars that add empty calories. Muscular Dystrophy Association
Eat oily fish 1–2×/week for omega-3s; avoid high-dose fish-oil pills unless your clinician advises. PMC
If HF is present, limit sodium (often ≤2 g/day per cardiology advice); avoid salty packaged foods. Muscular Dystrophy Association
Ensure vitamin D & calcium adequacy (food-first, supplement only to fill gaps); avoid mega-doses without lab-confirmed need. Frontiers
Hydrate sensibly; avoid dehydration (worsens fatigue/cramps) — unless your cardiologist prescribes fluid limits for HF. Muscular Dystrophy Association
Consider creatine (3–5 g/day) after clinician review; avoid if kidney issues or advised otherwise. PMC
Favor home-cooked meals with controlled portions; avoid frequent take-away with hidden sodium/fats. Muscular Dystrophy Association
Moderate caffeine/alcohol; avoid excess, which can worsen sleep/heart rhythm in susceptible people. AHA Journals
If swallowing is difficult, use softer textures and see a speech-language pathologist; avoid dry, crumbly food that increases aspiration risk. LGMD Awareness Foundation

Frequently asked questions

Is LGMDR7 the same as LGMD2G?
Yes. LGMD2G is the older name; LGMDR7 is the updated name for autosomal-recessive TCAP/telethonin disease. nmd-journal.com+1
What causes it?
Mutations in TCAP lead to loss of telethonin, a Z-disc protein that stabilizes muscle structure with titin. Weak fibers are more easily damaged during everyday use. Nature+1
When do symptoms start?
Often in the first or second decade, with hip/shoulder weakness and sometimes calf enlargement. PLOS+1
Will I get heart or breathing problems?
Risk is variable; some series report minimal cardiopulmonary disease, others report cardiomyopathy. That’s why regular screening is advised. ScienceDirect+1
Is there a cure?
Not yet. Gene therapy for TCAP is under investigation, but no approved disease-modifying therapy exists today. PubMed
What’s the best exercise?
Supervised, moderate aerobic plus gentle resistance; avoid maximal/eccentric overexertion and “no-pain-no-gain” approaches. Cochrane+1
Do steroids help like in Duchenne?
No consistent evidence supports chronic steroids in LGMDR7; risks often outweigh benefits outside specific indications. Focus on rehab and risk-based cardiac/respiratory care. PMC
Which vitamins or supplements are proven?
Evidence is modest at best. Creatine has the most supportive data for small strength gains; others (CoQ10, omega-3s, L-carnitine) have limited or mixed evidence. Always check interactions. PMC+2PMC+2
How is it diagnosed?
Clinical exam, CK elevation, EMG, muscle MRI/biopsy, and genetic testing confirming TCAP variants. NCBI
What does genetic counseling offer?
It explains autosomal recessive inheritance, tests relatives for carrier status, and reviews reproductive options. NCBI
If my echo is normal, do I still need checks?
Yes. Repeat screening is prudent because cardiac risks can evolve over time in some LGMD subtypes. AHA Journals
When are wheelchairs helpful?
Earlier than people think—using wheels extends independence and prevents dangerous falls and fatigue. LGMD Awareness Foundation
Are there anesthesia risks?
Anesthesia requires advance planning in muscular dystrophy; ensure teams follow current guidance and prepare for respiratory support. LGMD Awareness Foundation
What’s the outlook?
Progression varies. A 2024 cohort suggested median ~21 years from onset to walking-aid use, with slower progression in women—but individual trajectories differ. PubMed
How can I join research?
Ask your neuromuscular center about registries and upcoming TCAP gene therapy studies. Muscular Dystrophy Association+1